Literature DB >> 10076917

Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury.

M Miyazaki1, T Wada, N Shiota, S Takai.   

Abstract

The roles of angiotensin (Ang) II as produced by two different enzymes, angiotensin-converting enzyme (ACE) and chymase, were investigated in a canine experimental model where intima hyperplasia was induced by balloon catheterization in the common carotid and femoral arteries. The animals received oral candesartan cilexetil (3 mg/kg) or enalapril (10 mg/kg) twice a day for 5 weeks. After 1 week of active drug therapy, the common carotid and femoral arteries were unilaterally injured by balloon catheterization. In the common carotid arteries, both ACE and chymase activities were increased by the injury, with the increase in chymase activities being greater than that in ACE activities. In the femoral arteries, ACE, but not chymase, activities were significantly increased by the injury. Both candesartan cilexetil and enalapril reduced blood pressure almost equally. Enalapril increased plasma renin activity more strongly than did candesartan cilexetil, and significantly decreased vascular and plasma ACE activities. Candesartan cilexetil significantly suppressed the formation of intima hyperplasia in both the carotid and femoral arteries, while enalapril significantly suppressed intima hyperplasia in the femoral, but not in the carotid arteries. These results indicate that local Ang II production by ACE and chymase is involved in the hyperplasia seen in injured intima, and the difference in the inhibitory action of candesartan and enalapril reflects the extent of contribution of each enzyme. The effect of the ACE inhibitor, enalapril, depended on the activity of ACE, whereas that of the Ang II receptor antagonist, candesartan, was independent of ACE activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10076917     DOI: 10.1038/sj.jhh.1000745

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

1.  Deficiency of mouse mast cell protease 4 mitigates cardiac dysfunctions in mice after myocardium infarction.

Authors:  Yunzhe Wang; Cong-Lin Liu; Wenqian Fang; Xian Zhang; Chongzhe Yang; Jie Li; Jing Liu; Galina K Sukhova; Michael F Gurish; Peter Libby; Guo-Ping Shi; Jinying Zhang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-01-11       Impact factor: 5.187

2.  Initial reduction of oxidative stress by angiotensin receptor blocker contributes long term outcomes after percutaneous coronary intervention.

Authors:  Tadanori Noro; Naofumi Takehara; Kazuhiro Sumitomo; Toshiharu Takeuchi; Yoshinao Ishii; Jun-Ichi Kato; Jun-Ichi Kawabe; Naoyuki Hasebe
Journal:  Am J Cardiovasc Dis       Date:  2014-12-29

Review 3.  Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.

Authors:  Aina He; Guo-Ping Shi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 4.  Candesartan cilexetil: an update of its use in essential hypertension.

Authors:  Stephanie E Easthope; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.

Authors:  Ezequiel Balmori Melian; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet.

Authors:  M Miyazaki; H Sakonjo; S Takai
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.